OrbiMed, a US-based healthcare investment firm, has filed to raise up to $750 million for its fourth Asia-focused healthcare fund, nearly three years after it closed the predecessor fund, according to a US SEC document.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com